Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Methotrexate may leads to higher treatment responsea(up to 6 months) compared with placebo (low certainty).
The review found no eligible studies for this question.
Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Methotrexate showed no clear difference in participant global assessment of well‐being(up to 6 months) compared with placebo (low certainty).
Methotrexate showed no clear difference in serious adverse events(up to 6 months) compared with placebo (low certainty).
Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 28 days compared with placebo or control (low certainty).
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 36 weeks' gestation compared with placebo or control (low certainty).
Indomethacin showed no clear difference in all‐cause neonatal mortality before hospital discharge compared with placebo or control (moderate certainty).
Indomethacin showed no clear difference in proportion of infants requiring surgical ligation of PDA compared with placebo or control (moderate certainty).
Indomethacin showed no clear difference in NEC (≥ Bell stage 2) compared with placebo or control (low certainty).
Indomethacin showed no clear difference in mucocutaneous or gastrointestinal bleeding compared with placebo or control (low certainty).
Methotrexate may leads to higher disease response compared with placebo (low certainty).
The review found no eligible studies for this question.